Current and future therapies for inflammatory bowel disease

References

• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology126(6), 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet2(8044), 892–895 (1977).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment. Pharmacol. Therapeut.20(Suppl. 4), 60–65 (2004).
   PubMed Web of Science ®Google Scholar
• Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev. Gastroenterol. Disord.3(4), 210–218 (2003).
   PubMedGoogle Scholar
• Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (Online) (3), CD000543 (2003).
   Google Scholar
• Green JR, Gibson JA, Kerr GD et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator Group. Aliment. Pharmacol. Therapeut.12(12), 1207–1216 (1998).
   PubMed Web of Science ®Google Scholar
• The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann. Intern. Med.124(2), 204–211 (1996).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment. Pharmacol. Therapeut.19(2), 179–189 (2004).
   PubMed Web of Science ®Google Scholar
• Wright JP, O’Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig. Dis. Sci.38(10), 1837–1842 (1993).
   PubMedGoogle Scholar
• Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol.96(10), 2929–2933 (2001).
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med.114(1), 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol.5(1), 95–102 (2007).
   PubMed Web of Science ®Google Scholar
• Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology132(1), 66–75 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol.95(5), 1263–1276 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut40(6), 775–781 (1997).
   PubMed Web of Science ®Google Scholar
• Marteau P, Probert CS, Lindgren S et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut54(7), 960–965 (2005).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Stromberg U. Oral pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin. Gastroenterol. Hepatol.2(5), 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology113(5), 1465–1473 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Korelitz BI, Rutgeerts P et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology127(3), 723–729 (2004).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Sampietro GM et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology127(3), 730–740 (2004).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst. Rev. (Online) (1), CD003715 (2005).
   Google Scholar
• Modigliani R, Colombel JF, Dupas JL et al. Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology110(3), 688–693 (1996).
   PubMedGoogle Scholar
• Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. (Online) (4), CD000301 (2003).
   Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology121(2), 255–260 (2001).
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut35(3), 360–362 (1994).
   PubMed Web of Science ®Google Scholar
• Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet2(8099), 1086–1088 (1978).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology120(6), 1323–1329 (2001).
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol.5(1), 103–110 (2007).
   PubMed Web of Science ®Google Scholar
• Bossa F, Fiorella S, Caruso N et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am. J. Gastroenterol.102(3), 601–608 (2007).
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med.331(13), 836–841 (1994).
   PubMed Web of Science ®Google Scholar
• Thomsen OO, Cortot A, Jewell D et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N. Engl. J. Med.339(6), 370–374 (1998).
   PubMed Web of Science ®Google Scholar
• Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. (Online) (4), CD000296 (2005).
   Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology110(1), 45–51 (1996).
   PubMed Web of Science ®Google Scholar
• Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn’s disease – results of a 12-month study. Global Budesonide Study Group. Aliment. Pharmacol. Therapeut.12(2), 175–183 (1998).
   PubMed Web of Science ®Google Scholar
• Hellers G, Cortot A, Jewell D et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. The IOIBD Budesonide Study Group. Gastroenterology116(2), 294–300 (1999).
   PubMed Web of Science ®Google Scholar
• Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut32(9), 1071–1075 (1991).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology108(6), 1617–1621 (1995).
   PubMed Web of Science ®Google Scholar
• Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology79(2), 357–365 (1980).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Lemann M, Cassagnou M et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am. J. Gastroenterol.94(3), 674–678 (1999).
   PubMed Web of Science ®Google Scholar
• Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm. Bowel Dis.8(1), 10–15 (2002).
   PubMed Web of Science ®Google Scholar
• Gilat T, Suissa A, Leichtman G et al. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J. Clin. Gastroenterol.9(4), 415–417 (1987).
   PubMed Web of Science ®Google Scholar
• Turunen UM, Farkkila MA, Hakala K et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology115(5), 1072–1078 (1998).
   PubMed Web of Science ®Google Scholar
• Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis.7(4), 301–305 (2001).
   PubMed Web of Science ®Google Scholar
• Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis.12(7), 651–664 (2006).
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut37(5), 674–678 (1995).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sutherland L, Pearson D et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst. Rev. (Online) (2), CD000545 (2000).
   Google Scholar
• Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst. Rev. (Online) (2), CD000067 (2000).
   Google Scholar
• Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med.302(18), 981–987 (1980).
   PubMed Web of Science ®Google Scholar
• Sood A, Kaushal V, Midha V et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J. Gastroenterol.37(4), 270–274 (2002).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut55(1), 47–53 (2006).
   PubMed Web of Science ®Google Scholar
• Actis GC, Bresso F, Astegiano M et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment. Pharmacol. Therapeut.15(9), 1307–1311 (2001).
   PubMedGoogle Scholar
• Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Therapeut.14(12), 1561–1565 (2000).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology118(6), 1025–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol.5(2), 209–214 (2007).
   PubMed Web of Science ®Google Scholar
• Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst. Rev. (Online) (1), CD003459 (2005).
   Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N. Engl. J. Med.342(22), 1627–1632 (2000).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bollani S, Manzionna G et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigator-blind study. Dig. Liver Dis.35(9), 619–627 (2003).
   PubMedGoogle Scholar
• Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med.330(26), 1841–1845 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am. J. Gastroenterol.94(6), 1587–1592 (1999).
   PubMed Web of Science ®Google Scholar
• McDonald JW, Feagan BG, Jewell D et al. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. (Online) (2), CD000297 (2005).
   Google Scholar
• Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig. Dis. Sci.51(10), 1833–1840 (2006).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology125(2), 380–388 (2003).
   PubMed Web of Science ®Google Scholar
• Ogata H, Matsui T, Nakamura M et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut55(9), 1255–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Orth T, Peters M, Schlaak JF et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am. J. Gastroenterol.95(5), 1201–1207 (2000).
   PubMed Web of Science ®Google Scholar
• Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology117(6), 1271–1277 (1999).
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology117(6), 1278–1287 (1999).
   PubMed Web of Science ®Google Scholar
• Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn’s disease resistant to standard therapies. Aliment. Pharmacol. Therapeut.25(5), 557–567 (2007).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology126(2), 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology128(7), 1805–1811 (2005).
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J. Clin. Gastroenterol.35(2), 151–156 (2002).
   PubMed Web of Science ®Google Scholar
• van Balkom BP, Schoon EJ, Stockbrugger RW et al. Effects of anti-tumour necrosis factor-α therapy on the quality of life in Crohn’s disease. Aliment. Pharmacol. Therapeut.16(6), 1101–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts PJ, Hanauer SB et al. Infliximab therapy improves health related quality of life in ulcerative colitis patients. Am. J. Gastroenterol.100(s9), A792 (2005).
   PubMedGoogle Scholar
• Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol.99(1), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med.348(7), 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology126(6), 1593–1610 (2004).
   PubMed Web of Science ®Google Scholar
• Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs64(16), 1767–1777 (2004).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology124(4), 917–924 (2003).
   PubMed Web of Science ®Google Scholar
• Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nature Clin. Pract.3(4), 220–228 (2006).
   Google Scholar
• Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol. Clin N. Am.35(4), 837–855 (2006).
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345(15), 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatric Gastroenterol. Nutr.44(2), 265–267 (2007).
   PubMed Web of Science ®Google Scholar
• Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Therapeut.21(3), 251–258 (2005).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts PJ et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56, 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am. J. Gastroenterol.99(10), 1984–1989 (2004).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology129(3), 807–818 (2005).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance I. Certolizumab pegol, a humanised anti-TNF pegylated FAb´ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a Phase III study (PRECiSE). Gut54(Suppl. VII), A82 (2005).
   Web of Science ®Google Scholar
• Hanauer SB, Colombel JF, Sandborn WJ et al. Subcutaneous certolizumab pegol is effective in anti-TNF naïve patients and patient with prior infliximab use. Am. J. Gastroenterol.101(9 Suppl), S435 (2006).
   Google Scholar
• Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353(18), 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353(4), 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to α-4 integrin. Aliment. Pharmacol. Therapeut.16(4), 699–705 (2002).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med.352(24), 2499–2507 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg G, Wild G et al. Efficacy and safety of a humanized α4β7 antibody in active Crohn’s disease. Gastroenterology124(4 Suppl. 1), A25–A26 (2003).
   Web of Science ®Google Scholar
• van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut53(11), 1646–1651 (2004).
   PubMed Web of Science ®Google Scholar
• Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment. Pharmacol. Therapeut.23(10), 1403–1413 (2006).
   PubMed Web of Science ®Google Scholar
• Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharmacol. Therapeut.19(3), 281–286 (2004).
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey WY, Wedel MK et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin. Gastroenterol. Hepatol.5(2), 215–220 (2007).
   PubMed Web of Science ®Google Scholar
• Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn’s disease. N. Engl. J. Med.352(21), 2193–2201 (2005).
   PubMed Web of Science ®Google Scholar
• Hommes DW, Mikhajlova TL, Stoinov S et al. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut55(8), 1131–1137 (2006).
   PubMed Web of Science ®Google Scholar
• Plevy S, Salzberg B, Hommes DW et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for the treatment of severe steroid-refractory ulcerative colitis: results of a Phase I study (abstract). Gastroenterology126,A75 (2004).
   Google Scholar
• Targan SR, Salzberg BA, Mayer L et al. A Phase I–II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids (IVSR-UC) (abstract). Gastroenterology128, A75 (2005).
   Google Scholar
• Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med.351(20), 2069–2079 (2004).
   PubMed Web of Science ®Google Scholar